{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-010000","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2022-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.189578+00:00","generated_at":"2026-06-27T12:52:09.707474+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiora Pharmaceuticals appoints Erin Parsons to board; Stephen From resigns as Executive Chairman","bullets":["Stephen From voluntarily resigned as Executive Chairman and board member effective Jan 31, 2022; no disagreement cited.","From receives 18 monthly severance payments of $33,333, a lump sum of $300,000, COBRA subsidies, and accelerated vesting.","Erin Parsons appointed as independent Class III director; she founded Parsons Medical Communications and has ophthalmic expertise.","Paul Chaney appointed as non-executive Chairman, previously serving as Lead Independent Director."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-010000","json":"https://secwatch.observer/filing/0001104659-22-010000.json","markdown":"https://secwatch.observer/filing/0001104659-22-010000.md","text":"https://secwatch.observer/filing/0001104659-22-010000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922010000/0001104659-22-010000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922010000/tm225039d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:52:09.707474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01c8ecbc07","claim":"Paul Chaney was appointed as non-executive Chairman at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"the Board appointed Paul Chaney as non-executive Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922010000/0001104659-22-010000-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"non-executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"2988af9e7a","claim":"Erin Parsons was appointed as Director at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"On January 31, 2022, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed Erin Parsons as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922010000/0001104659-22-010000-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5fb7cfa5b7","claim":"Stephen From resigned as Executive Chairman at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"Effective of January 31, 2022, Stephen From voluntarily resigned as Executive Chairman of the Company and as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922010000/0001104659-22-010000-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}